Perspectives

Drug Pipeline Quarterly Update: September 2021

Drugs in review, drugs with expiring patents, generic availability and more.

September 30, 2021

These quarterly pipeline wrap-ups include new molecular entity approvals, drugs with approvable status from the FDA, potential blockbuster drugs and the dates of expected FDA approval, names of top selling brand-name drugs with generic availability in the past 12 months and names of top selling brand-name drugs that have patents expiring soon.

September 2021 Quarterly Drug Pipeline Update
September 2021 Quarterly Specialty Drug Pipeline Update

About Prime Therapeutics

Prime Therapeutics LLC (Prime) is a diversified pharmacy solutions organization serving health plans, employers and government programs. Prime is collectively owned by 19 Blue Cross and Blue Shield Plans, subsidiaries or affiliates of those plans. Magellan Rx Management LLC, a Prime Therapeutics LLC Company, is a pioneer in specialty and medical drug management and a leader in serving public sector state government programs. Together Prime and Magellan Rx provide a wide range of clients with solutions that bridge the distance between medical and pharmacy management. For more information visit primetherapeutics.com and magellanrx.com or follow us on X (Twitter) at @Prime_PBM and @Magellan_Rx.

Related news

Perspectives

May 1, 2024

Prime Therapeutics releases new clinical insights report, “Weight management: A holistic journey”

Report encourages providers to consider health contexts and lifestyle modifications as well as personal preferences and current guidelines when prescribing GLP-1s for weight loss

Read More

Perspectives

April 30, 2024

AMCP 2024: Behind the GLP-1 Spotlight Session with Ben Urick

Urick, senior principal health outcomes researcher, shares more about his Spotlight Session at the Academy of Managed Care Pharmacy (AMCP)’s Annual Meeting

Read More

Perspectives

April 30, 2024

Quarterly Drug Pipeline

Clinical insights and competitive intelligence on anticipated drugs in development

Read More
View all news